APA

Daghistani M., Marin D., Khorashad J. S., Wang L., May P. C., Paliompeis C., Milojkovic D., De Melo V. A., Gerrard G., Goldman J. M., Apperley J. F., Clark R. E., Foroni L. & Reid A. G. (20110222). EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. : Blood.

Chicago

Daghistani Mustafa, Marin David, Khorashad Jamshid Sorouri, Wang Lihui, May Philippa C, Paliompeis Christos, Milojkovic Dragana, De Melo Valeria A, Gerrard Gareth, Goldman John M, Apperley Jane F, Clark Richard E, Foroni Letizia and Reid Alistair G. 20110222. EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. : Blood.

Harvard

Daghistani M., Marin D., Khorashad J. S., Wang L., May P. C., Paliompeis C., Milojkovic D., De Melo V. A., Gerrard G., Goldman J. M., Apperley J. F., Clark R. E., Foroni L. and Reid A. G. (20110222). EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. : Blood.

MLA

Daghistani Mustafa, Marin David, Khorashad Jamshid Sorouri, Wang Lihui, May Philippa C, Paliompeis Christos, Milojkovic Dragana, De Melo Valeria A, Gerrard Gareth, Goldman John M, Apperley Jane F, Clark Richard E, Foroni Letizia and Reid Alistair G. EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. : Blood. 20110222.